{"id":39881,"date":"2025-11-28T12:00:00","date_gmt":"2025-11-28T05:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=39881"},"modified":"2025-11-28T12:00:00","modified_gmt":"2025-11-28T05:00:00","slug":"imugene-and-jw-therapeutics-announce-a-collaboration-to-advance-oncarlytics-and-carteyva-combination-in-solid-tumours","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=39881","title":{"rendered":"Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva\u00ae Combination in Solid Tumours"},"content":{"rendered":"<ul type=\"disc\">\n<li>Imugene and JW Therapeutics (<span class=\"xn-location\">Shanghai<\/span>) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene&#8217;s onCARlytics (CF33-CD19) oncolytic virus and JW&#8217;s CD19 CAR-T cell therapy, Carteyva\u00ae, in refractory solid tumors.<\/li>\n<li>The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in <span class=\"xn-location\">China<\/span> targeting difficult-to-treat cancers.<\/li>\n<li>This approach represents a first-in-class &#8220;mark and kill&#8221; strategy, leveraging\u00a0oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.<\/li>\n<li>The collaboration leverages\u00a0JW&#8217;s commercial CAR-T infrastructure and Imugene&#8217;s clinical onCARlytics platform to generate preclinical and clinical data and inform further clinical development.<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SYDNEY<\/span> and <span class=\"xn-location\">SHANGHAI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 27, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, and JW Therapeutics (<span class=\"xn-location\">Shanghai<\/span>) Co., LTD (HKEX:2126), a leading biotechnology company focused on cell-based immunotherapies, today announced a co-development collaboration to evaluate the combination of Imugene&#8217;s oncolytic virus CF33-CD19 (onCARlytics) and JW&#8217;s Carteyva\u00ae\u2014a CD19-directed autologous CAR-T cell therapy\u2014for patients with advanced solid tumors.\u00a0<\/p>\n<p>This collaboration includes preclinical <i>in vitro<\/i> and <i>in vivo<\/i> studies, followed by a Phase 1 investigator-initiated trial to be conducted exclusively in <span class=\"xn-location\">China<\/span> at premier CAR-T clinical centers. The approach utilizes Imugene&#8217;s CF33-CD19 virus to induce CD19 expression on tumor cells, rendering them susceptible to targeting by CD19 CAR-T therapies\u2014a transformative &#8220;mark and kill&#8221; strategy.<\/p>\n<p>&#8220;This collaboration allows us to validate our onCARlytics platform in combination with an approved autologous CAR-T product,&#8221; said <span class=\"xn-person\">Leslie Chong<\/span>, Managing Director and CEO of Imugene. &#8220;We believe Carteyva\u00ae which is already approved in blood cancer is an ideal choice, and this initiative enables us to generate impactful data efficiently while exploring a breakthrough treatment paradigm for solid tumours.&#8221;<\/p>\n<p>With clear go\/no-go decision points, and milestones, the collaboration ensures disciplined capital allocation while enabling strategic flexibility.<\/p>\n<p>For more information please contact:<\/p>\n<p><span class=\"xn-person\">Leslie Chong<\/span><br \/>Managing Director and Chief Executive Officer<br \/><a href=\"mailto:info@imugene.com\" target=\"_blank\" rel=\"nofollow\">info@imugene.com<\/a><\/p>\n<p>Investor Enquiries<br \/><a href=\"mailto:shareholderenquiries@imugene.com\" target=\"_blank\" rel=\"nofollow\">shareholderenquiries@imugene.com<\/a><\/p>\n<p>Media Enquiries<br \/><a href=\"mailto:communications@imugene.com\" target=\"_blank\" rel=\"nofollow\">communications@imugene.com<\/a><\/p>\n<p>Connect with us on LinkedIn <a href=\"https:\/\/au.linkedin.com\/company\/imugene\" target=\"_blank\" rel=\"nofollow\">@Imugene Limited<\/a><br \/>Follow us on Twitter <a href=\"https:\/\/twitter.com\/TeamImugene\" target=\"_blank\" rel=\"nofollow\">@TeamImugene<\/a><br \/>Watch us on YouTube <a href=\"https:\/\/www.youtube.com\/c\/ImugeneLimited\" target=\"_blank\" rel=\"nofollow\">@ImugeneLimited<\/a><\/p>\n<p>About Imugene (ASX:IMU)<\/p>\n<p>Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that\u00a0seek\u00a0to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies\u00a0seek\u00a0to harness the body&#8217;s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.\u00a0<\/p>\n<p>Our pipeline includes an\u00a0off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene\u00a0zapreleucel) which targets CD19 to treat blood cancers.\u202fOur pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR\u00a0T&#8217;s\u00a0for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.\u00a0<\/p>\n<p>Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe\u00a0Imugene&#8217;s\u00a0immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.\u202f<\/p>\n<p>About JW Therapeutics (HKEX: 2126)<\/p>\n<p>JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in\u00a0China\u00a0and beyond, and to leading the healthy and standardized development of\u00a0China&#8217;s\u00a0cell immunotherapy industry. For more information, please visit\u00a0<a href=\"http:\/\/www.jwtherapeutics.com\/\" target=\"_blank\" rel=\"nofollow\">www.jwtherapeutics.com<\/a>.<\/p>\n<p><span class=\"xn-person\">Daniel Tu<\/span><br \/>VP, Head of Corporate Strategy, Business Development &amp; Alliance<br \/><a href=\"mailto:daniel.tu@jwtherapeutics.com\" target=\"_blank\" rel=\"nofollow\">daniel.tu@jwtherapeutics.com<\/a><\/p>\n<p><i>Release authorised by the Managing Director and Chief Executive Officer Imugene Limited and Chief Executive Officer JW Therapeutics.<\/i><\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<ul type=\"disc\">\n<li>Imugene and JW Therapeutics (<span class=\"xn-location\">Shanghai<\/span>) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene&#8217;s onCARlytics (CF33-CD19) oncolytic virus and JW&#8217;s CD19 CAR-T cell therapy, Carteyva\u00ae, in refractory solid tumors.<\/li>\n<li>The collaboration includes preclinical studies, followed by a Phase 1 investigator-initiated trial (IIT) in <span class=\"xn-location\">China<\/span> targeting difficult-to-treat cancers.<\/li>\n<li>This approach represents a first-in-class &#8220;mark and kill&#8221; strategy, leveraging\u00a0oncolytic virus-induced CD19 expression to make solid tumors targetable by CD19-CAR T cells.<\/li>\n<li>The collaboration leverages\u00a0JW&#8217;s commercial CAR-T infrastructure and Imugene&#8217;s clinical onCARlytics platform to generate preclinical and clinical data and inform further clinical development.<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SYDNEY<\/span> and <span class=\"xn-location\">SHANGHAI<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 27, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, and JW Therapeutics (<span class=\"xn-location\">Shanghai<\/span>) Co., LTD (HKEX:2126), a leading biotechnology company focused on cell-based immunotherapies, today announced a co-development collaboration to evaluate the combination of Imugene&#8217;s oncolytic virus CF33-CD19 (onCARlytics) and JW&#8217;s Carteyva\u00ae\u2014a CD19-directed autologous CAR-T cell therapy\u2014for patients with advanced solid tumors.\u00a0<\/p>\n<p>This collaboration includes preclinical <i>in vitro<\/i> and <i>in vivo<\/i> studies, followed by a Phase 1 investigator-initiated trial to be conducted exclusively in <span class=\"xn-location\">China<\/span> at premier CAR-T clinical centers. The approach utilizes Imugene&#8217;s CF33-CD19 virus to induce CD19 expression on tumor cells, rendering them susceptible to targeting by CD19 CAR-T therapies\u2014a transformative &#8220;mark and kill&#8221; strategy.<\/p>\n<p>&#8220;This collaboration allows us to validate our onCARlytics platform in combination with an approved autologous CAR-T product,&#8221; said <span class=\"xn-person\">Leslie Chong<\/span>, Managing Director and CEO of Imugene. &#8220;We believe Carteyva\u00ae which is already approved in blood cancer is an ideal choice, and this initiative enables us to generate impactful data efficiently while exploring a breakthrough treatment paradigm for solid tumours.&#8221;<\/p>\n<p>With clear go\/no-go decision points, and milestones, the collaboration ensures disciplined capital allocation while enabling strategic flexibility.<\/p>\n<p>For more information please contact:<\/p>\n<p><span class=\"xn-person\">Leslie Chong<\/span><br \/>Managing Director and Chief Executive Officer<br \/><a href=\"mailto:info@imugene.com\" target=\"_blank\" rel=\"nofollow\">info@imugene.com<\/a><\/p>\n<p>Investor Enquiries<br \/><a href=\"mailto:shareholderenquiries@imugene.com\" target=\"_blank\" rel=\"nofollow\">shareholderenquiries@imugene.com<\/a><\/p>\n<p>Media Enquiries<br \/><a href=\"mailto:communications@imugene.com\" target=\"_blank\" rel=\"nofollow\">communications@imugene.com<\/a><\/p>\n<p>Connect with us on LinkedIn <a href=\"https:\/\/au.linkedin.com\/company\/imugene\" target=\"_blank\" rel=\"nofollow\">@Imugene Limited<\/a><br \/>Follow us on Twitter <a href=\"https:\/\/twitter.com\/TeamImugene\" target=\"_blank\" rel=\"nofollow\">@TeamImugene<\/a><br \/>Watch us on YouTube <a href=\"https:\/\/www.youtube.com\/c\/ImugeneLimited\" target=\"_blank\" rel=\"nofollow\">@ImugeneLimited<\/a><\/p>\n<p>About Imugene (ASX:IMU)<\/p>\n<p>Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that\u00a0seek\u00a0to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies\u00a0seek\u00a0to harness the body&#8217;s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.\u00a0<\/p>\n<p>Our pipeline includes an\u00a0off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene\u00a0zapreleucel) which targets CD19 to treat blood cancers.\u202fOur pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR\u00a0T&#8217;s\u00a0for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.\u00a0<\/p>\n<p>Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe\u00a0Imugene&#8217;s\u00a0immuno-oncology therapies may become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.\u202f<\/p>\n<p>About JW Therapeutics (HKEX: 2126)<\/p>\n<p>JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in\u00a0China\u00a0and beyond, and to leading the healthy and standardized development of\u00a0China&#8217;s\u00a0cell immunotherapy industry. For more information, please visit\u00a0<a href=\"http:\/\/www.jwtherapeutics.com\/\" target=\"_blank\" rel=\"nofollow\">www.jwtherapeutics.com<\/a>.<\/p>\n<p><span class=\"xn-person\">Daniel Tu<\/span><br \/>VP, Head of Corporate Strategy, Business Development &amp; Alliance<br \/><a href=\"mailto:daniel.tu@jwtherapeutics.com\" target=\"_blank\" rel=\"nofollow\">daniel.tu@jwtherapeutics.com<\/a><\/p>\n<p><i>Release authorised by the Managing Director and Chief Executive Officer Imugene Limited and Chief Executive Officer JW Therapeutics.<\/i><\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-39881","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/39881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39881"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/39881\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}